Fortis Healthcare Limited , one of India's leading integrated healthcare delivery service providers, has announced a significant expansion of its presence in the Delhi-NCR region. The company's wholly-owned subsidiary, International Hospital Limited (IHL), has entered into a 15-year lease agreement with RR Lifesciences Limited for a fully operational 200-bed multi-specialty hospital in Greater Noida.

Strategic Expansion

The newly leased facility, which will operate as Fortis Hospital Greater Noida, marks a strategic move for Fortis Healthcare. This addition brings the company's total bed capacity in the Delhi-NCR region to approximately 2,000 beds, strengthening its position as a key healthcare provider in the area.

Facility Details

The hospital is built on a 1.35-acre land parcel leased from UPSIDA (Uttar Pradesh State Industrial Development Authority) and boasts a built-up area of 2.7 lakh sq. ft. Notably, the facility has the potential to expand its capacity by an additional 50 beds within the existing setup, potentially increasing the total bed count to 250.

Financial Arrangements

Under the terms of the agreement, IHL will pay a monthly rent of Rs. 2.40 crore plus applicable GST to RR Lifesciences Pvt Ltd, subject to periodic escalation. Additionally, IHL will provide a refundable security deposit of Rs. 60 crore.

Strategic Location

The hospital's location is strategically advantageous, being well-connected by the Greater Noida Expressway, Metro (Aqua line), Yamuna Expressway, and Eastern Peripheral Expressway. It is also situated just 34 km from the upcoming Jewar International Airport, positioning it to serve a growing population in the rapidly developing Greater Noida area.

Management's Perspective

Dr. Ashutosh Raghuvanshi, MD & CEO of Fortis Healthcare Limited, commented on the development: "The addition of Fortis Hospital Greater Noida underlines our commitment to strengthening healthcare delivery across NCR. Greater Noida is emerging as an important hub, driven by urbanisation, industrial growth, and rising patient demand. With this expansion, we are not only enhancing access to advanced tertiary care but also reinforcing Fortis' leadership in the region."

Operational Control

With this lease agreement, Fortis will assume complete operational and financial control of the hospital, allowing it to consolidate the facility's performance within its network. The company had previously been managing the facility under an Operations & Management (O&M) arrangement since its launch in October 2022.

Future Prospects

This expansion aligns with Fortis Healthcare's strategy to strengthen its presence in key markets and meet the growing healthcare needs of the Delhi-NCR region. The company expects to leverage its existing facilities in the region to drive synergies and ramp up operations quickly.

Corporate Restructuring

In a separate development, Fortis Healthcare has also announced the completion of a corporate restructuring process. The company has filed a certified copy of an order from the National Company Law Tribunal, Chandigarh Bench, with the Registrar of Companies. This filing brings into effect a Composite Scheme of Arrangement involving International Hospital Limited, Fortis Hospitals Limited, and Fortis Hospotel Limited, all of which are direct or indirect wholly-owned subsidiaries of Fortis Healthcare.

As Fortis Healthcare continues to expand its footprint and streamline its corporate structure, these moves are expected to enhance its ability to deliver high-quality, patient-centric healthcare services across its growing network.

Fortis Healthcare , one of India's leading healthcare providers, has announced robust financial results for the first quarter of fiscal year 2026, along with significant expansion plans that aim to strengthen its market position.

Strong Financial Performance

The company reported impressive growth in its Q1 FY26 results:

• Consolidated revenue increased by 16.60% to INR 2,167.00 crore
• Operating EBITDA rose by 43.20% to INR 491.00 crore, with margins expanding to 22.60% from 18.40% in Q1 FY25
• Profit After Tax (PAT) grew by 56.80% to INR 260.00 crore

Hospital Business Highlights

Fortis Healthcare's hospital business showed remarkable progress:

• Revenue grew by 18.60% to INR 1,838.00 crore
• Operating EBITDA margin improved to 22.10% from 18.50% in the corresponding quarter last year
• Average Revenue Per Occupied Bed (ARPOB) increased by 10.20% to INR 2.65 crore per annum
• Occupancy rates improved to 69.00% compared to 67.00% in Q1 FY25

Diagnostics Business Performance

The diagnostics arm, Agilus, also demonstrated strong growth:

• Gross revenue increased by 7.40% to INR 368.80 crore
• Operating EBITDA margin expanded significantly to 23.00% from 16.10% in Q1 FY25
• Conducted 10.13 million tests, representing a 5.80% growth year-over-year

Expansion Strategies

Fortis Healthcare has outlined ambitious expansion plans to further solidify its market presence:

1. O&M Services Agreement with Gleneagles India: In July 2025, Fortis entered into an Operation and Maintenance Services agreement with Gleneagles India. This strategic move will allow Fortis to manage operations of approximately 700 beds across five hospitals and a clinic within the Gleneagles India network, expanding its footprint in key metro cities.

2. Acquisition of Shrimann Superspecialty Hospital: The company consummated the acquisition of Shrimann Superspecialty Hospital in Jalandhar, Punjab, adding 228 beds to its network. This acquisition has strengthened Fortis' presence in Punjab, increasing its bed capacity in the region from about 800 to 1,000 beds.

3. Long-term Growth Plans: Fortis Healthcare aims to add over 1,000 new beds through Gleneagles operations and maintenance activities and the Shrimann acquisition.

4. Focus on High-Profit Specialties: The company reported that 63.00% of its revenue comes from high-profit specialty services, including Oncology, Neurosciences, Cardiac Sciences, Gastroenterology, Orthopedics, and Renal Sciences.

5. International Patient Revenue: Fortis is working to increase its international patient revenue, which grew by 21.00% to INR 154.00 crore in Q1 FY26, contributing 7.90% to overall hospital business revenues.

6. Diagnostics Margin Improvement: The company is targeting a diagnostics margin improvement to 23.00%, which it has already achieved in Q1 FY26.

Dr. Ashutosh Raghuvanshi, MD and CEO of Fortis Healthcare, commented on the results, stating, "We have witnessed a healthy start to the financial year, as demonstrated in our Q1 earnings for both hospital and diagnostic businesses. The recently executed O&M services agreement with Gleneagles India expands our geographic footprint and provides an opportunity to leverage our combined strengths to optimize operations and enhance efficiencies."

With these strategic expansions and strong financial performance, Fortis Healthcare is positioning itself for sustained growth in the Indian healthcare sector. The company's focus on high-profit specialties, expansion of bed capacity, and improvement in diagnostics business efficiency are expected to drive its future performance.